Phase II CHOOSE Trial: Integrated mHealth PrEP Support Plus DoxyPEP Strategy for Young People at HIV Risk

References

1. 1.Australian Government Department of Health. (2023). Pre-exposure prophylaxis (PrEP) for HIV prevention. https://www.health.gov.au/topics/communicable-diseases/hiv/prevention/pre-exposure-prophylaxis-prep
2. 2.Becasen, J. S., Denard, C. L., Mullins, M. M., Higa, D. H., & Sipe, T. A. (2019). Estimating the Prevalence of HIV and Sexual Behaviors Among the US Transgender Population: A Systematic Review and Meta-Analysis, 2006-2017. American Journal of Public Health, 109(1), e1-e8. https://doi.org/10.2105/AJPH.2018.304727
3. 3.Centers for Disease Control and Prevention. (2023). HIV Surveillance Report, 2021. CDC HIV Surveillance Reports. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
4. 4.Hemming, K., Haines, T. P., Chilton, P. J., Girling, A. J., & Lilford, R. J. (2015). The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ, 350, h391. https://doi.org/10.1136/bmj.h391
5. 5.Landovitz, R. J., Donnell, D., Clement, M. E., Hanscom, B., Cottle, L., Coelho, L., ... & Burns, D. N. (2021). Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. New England Journal of Medicine, 385(7), 595-608. https://doi.org/10.1056/NEJMoa2101016
6. 6.Luetkemeyer, A. F., Donnell, D., Dombrowski, J. C., Cohen, S., Grabow, C., Brown, C. E., ... & Celum, C. (2023). Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. New England Journal of Medicine, 388(14), 1296-1306. https://doi.org/10.1056/NEJMoa2211934
7. 7.Parsons, J. T., Rendina, H. J., Lassiter, J. M., Whitfield, T. H., Starks, T. J., & Grov, C. (2017). Uptake of HIV Pre-Exposure Prophylaxis (PrEP) in a National Cohort of Gay and Bisexual Men in the United States. Journal of Acquired Immune Deficiency Syndromes, 74(3), 285-292. https://doi.org/10.1097/QAI.0000000000001251
8. 8.Spinelli, M. A., Glidden, D. V., Grinsztejn, B., Woodd, S. L., Fleming, P., Isbell, S., ... & Grant, R. M. (2018). Discontinuation of oral HIV pre-exposure prophylaxis (PrEP) and its barriers and facilitators among men who have sex with men in Brazil, Peru, and Thailand. PLoS One, 13(4), e0195774. https://doi.org/10.1371/journal.pone.0195774
9. 9.Westat. (2024). Combatting HIV Or Other STIs Early (CHOOSE): An Integrated Strategy of Pre-Exposure Prophylaxis (PrEP) Mobile Health (mHealth) Support and Doxycycline Post-Exposure Prophylaxis (DoxyPEP). ClinicalTrials.gov. NCT07510048. https://clinicaltrials.gov/study/NCT07510048
10. 10.Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., ... & Bolan, G. A. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1-187. https://doi.org/10.15585/mmwr.rr7004a1